Improvement of Fat Redistribution, Insulin Resistance and Hepatic Fatty Infiltration in HIV-Associated Lipodystrophy Syndrome by Pioglitazone: A Case Report

Journal of the Medical Association of Thailand

Volumn 87, Issue 2, 2004, Pages 166-172

  Prasithsirikul, Wisit ^a   Bunnag, Pongamorn ^b  

^a Bamrasnaradura Infectious Disease Institute   (Thailand)

^b NONE

Author keywords

HIV Associated Lipodystrophy; Insulin Resistance; Pioglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; ENALAPRIL; GLIPIZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; NEVIRAPINE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEINASE INHIBITOR; SIMVASTATIN; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY FAT; CASE REPORT; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES CONTROL; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; OUTCOMES RESEARCH; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 1842660808     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-70.
2. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Dfic Syndr 1999; 21: 107-13.
3. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy and insulin resistance due to HIV protease inhibitors. AIDS 1998; 12: F51-8.
4. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-5.
5. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999; 13: 1287-93.
6. Mauss S. HIV-associated lipoidystrophy syndrome. AIDS 2000; 14 (Supp 13): S197-207.
7. Safrin S, Grunfield C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-505.
8. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-9.
9. Walli R, Herfort O, Michl GM, Demant T, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-73.
10. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J AIDS 1999; 21: 209-16.
11. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84: 1925-31.
12. Hadigan C, Corcoran C, Stanley T, et al. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrind Metab 2000; 85: 35-41.
13. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000; 160: 2050-6.
14. Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med. 1999; 16: 179-92.
15. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
16. Madge S, Kinloch-de-Loes S, Mercy D, Johnson MA, Weller IV. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS 1999; 13: 735-7.
17. Leow MKS, Addy CL, Mantzoros CS. Human Immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: Clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003; 88: 1961-76.
18. Zhang B, MacNaul K, Szalsowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84: 4274-7.
19. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR-gamma/RXR heterodimer. J Endocrinol 2000; 164: 407-10.
20. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease-inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998; 351: 1881-3.
21. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
22. Carter VM, Hoy JF, Bailey M, et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: It all depends on the definition, HIV Med 2001; 2: 174-80.
23. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease-inhibitors: A prospective cohort study. Lancet 2001; 357: 592-8.
24. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities afterswitching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-10.
25. Saint-Marc T, Touraine JL. The effects of discontinuing starvudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13: 2188-9.
26. Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART. AIDS 1999; 13: 2479-81.
27. Mauss S, Wolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann Intern Med 1999; 131: 313-4.
28. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13: 2099-103.
29. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome. A randomized controlled trial. JAMA 2000; 284: 472-7.
30. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-74.
31. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosigliytazone: A pilot study. J Acquir Immune Defic Syndr 2002; 31: 163-70.
32. Sutinen J, Hakkinen AM, Wesrebacka J, et al. Rosiglitazone in the treatmen of HAART associated lipodystrophy (HAL): A randomized, double-blind, placebo-controlled study. Program of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle WA 2002 (Abstract LB 13).
33. Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003; 17: 770-2.